3Giles F, Estey e, O'Brien S. gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer, 2003,98(10):2094.
4Emmanouilides C. Radioimmunotherapy for non-Hodgkin's lymphoma. Semin Oncol, 2003,30(4):531.
5McLaughlin P, Grillo-Lopez A J, Link B K, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma : half of patients respond to a four-dose treatment program . J Clin Oncol, 1998,16(8):2825.
6Hung M C, Lau Y K. Basic sciene of HER-2/neu: a review. Semin Oncol,1999,26(4 Suppl 12):51.
7Cobleigh M A, Vogel C L, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol,1999,17(9):2639.
8Slamon D J, Leyland-jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001,334(11):783.
9Burstein H J, Harris L N, Marcom P K, et al. Trastuzumab and vinorelbine as first-line therapy for HER2 -overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol, 2003,21(15):2889.
10Druker H J,Lydon N B.Lessons learned form the development of an tyrosine Kinase inhibitor for chronic myelogenous leukemia. J Clin invest,2000,105(1):37.
二级参考文献12
1Leonard DS,Hill AD,Kelly L,et al.Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer[J].Br J Surg,2002,89(3):262-271.
2Druker BJ,Lydon NB.Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia[J].J Clin Invest,2000,105(1):3-7.
3Joensuu H.Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib(Glivec,Gleevec)[J].Med Klin,2002,97(Suppl 1):28-30.
4Pollack VA,Savage DM,Baker DA,et al.Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774:dynamics of receptor inhibition in situ and antitumor effects in athymic mice[J].J Pharmaeol Exp Ther,1999,291(2):739-748.
5Hidalgo M,Siu LL,Nemunaitis J,et al.Phase I and pharmacologic study of OSI-774,an epidermal growth factor receptor tyrosine kinase inhibitor,in patients with advanced sofid malignancies[J].J Clin Oncol,2001,19(13):3267-3279.
6Baselga J.The EGFR as a target for anticaneer therapy-focus on cetuximab[J].Eur J Cancer,2001,37(Suppl 4):S16-22.
7Lynch DH,Yang XD.Therapeutic potential of ABX-EGF:a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment[J].Semin Oncol,2002,29(1 Suppl 4):47-50.
8Gorre ME,Mohammed M,Ellwood K,et al.Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or arnplification[J].Science,2001,293(5531):876-880.
9Yu JL,Rak JW,Coomber BL,et al.Effect of p53 status on tumor response to antiangiogenie therapy[J].Science,2002,295(5559):1526-1528.
10Mrsie M,Grgie M,Budisie Z,et al.Trastuzumab in the treatment of advanced breast cancer:single-center experience[J].Ann Oneol,2001,12(Suppl 1):S95-96.
7Gregoriadis G. Liposome Technology ( Vol 3 ) [ M ]. Boca Raton: CRC Press, 1984:75-94.
8Jones PF, Jakubowicz T, Pitossi FJ, et al. Molecular cloning and identification of a serine/threonine protein kinase of the second messenger subfamily [ J ]. Proc Natl Acad Sci USA, 1991, 88(10) :4171.
9Datta SR, Brunet A, Greenberg ME. Cellular survival : a play in three Akts[J]. Genes Dev, 1999, 13(22) : 2905.
10Perez - Soler R. Phase Ⅱ clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI -774) in non- small- cell lung cancer [ J]. Clin Lung Cancer, 2004, 6 ( Suppl 1) :S20.
